Here are the 10-Q quarterly reports from TriSalus Life Sciences, Inc. Warrant (TLSIW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TLSIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLSIW filings page.
TriSalus Life Sciences, Inc., an oncology-focused medical technology company, reported Q2 2026 revenue of $11,407 thousand, with cost of goods sold of $1,508 thousand and gross profit of $9,899 thousand. Operating expenses included research and development of $3,137 thousand, sales and marketing of $11,416 thousand, and general and administrative costs of $5,159 thousand. Loss from operations was $9,813 thousand, leading to a net loss of $9,187 thousand, or $0.16 per share, compared with a net loss attributable to common stockholders of $9,002 thousand, or $0.27 per share, in Q2 2025.
For the six months ended June 30, 2026, revenue was $20,306 thousand and net loss was $7,648 thousand, versus revenue of $20,380 thousand and net loss of $18,663 thousand in the prior-year period. Results reflected gains of $6,469 thousand from changes in fair value of SEPA, warrant and revenue base redemption liabilities and a $6,406 thousand gain from remeasurement of the contingent earnout liability.
Cash and cash equivalents increased to $46,288 thousand at June 30, 2026 from $20,439 thousand at December 31, 2025, mainly from $42,625 thousand of net proceeds from common stock issuances. Net cash used in operating activities was $16,609 thousand. Long-term debt under the OrbiMed Credit Agreement totaled $33,065 thousand, and total liabilities of $55,898 thousand were supported by stockholders’ equity of $6,550 thousand, compared with a stockholders’ deficit at year-end 2025.
TriSalus Life Sciences, Inc. reported first‑quarter 2026 revenue of $8.9 million, slightly below the prior year’s $9.2 million, but generated net income of $1.5 million versus a $10.4 million loss a year earlier. The swing to profit was driven mainly by non‑cash gains from remeasuring warrant, earnout and revenue‑based redemption liabilities.
Gross profit held essentially flat at $7.7 million, while operating expenses rose modestly as the company continued investing in R&D and commercial growth for its PEDD delivery systems and nelitolimod. Cash and cash equivalents increased sharply to $56.6 million, primarily from a February equity offering that raised about $42.6 million net.
Total assets doubled to $71.0 million, and stockholders’ equity improved from a deficit of $33.9 million at year‑end 2025 to positive equity of $12.8 million at March 31, 2026. Long‑term debt under the OrbiMed credit facility remained around $33.1 million, with associated warrants and revenue‑based redemption obligations continuing to be marked to fair value each quarter.